Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model
作者:Nour Karra、Taher Nassar、Alina Nemirovski Ripin、Ouri Schwob、Jürgen Borlak、Simon Benita
DOI:10.1002/smll.201301417
日期:2013.12.20
and cytotoxicity of this targeted delivery system in lung cancer cells over‐expressing EGFR. A quantitative measure of the high binding affinity of INPs to EGFR is demonstrated using surface plasmon resonance. In vivo tolerability and enhanced efficacy of cetuximab pcpl INPs in a metastatic lung cancer model are reported. Its therapeutic efficacy in A549‐luc‐C8 lung tumors is shown using non‐invasive
表皮生长因子受体(EGFR)的异常信号传导在多种人类癌症中很常见,并且在大多数非小细胞肺癌病例中也被过度表达。为了开发分子靶向疗法,设计了西妥昔单抗偶联的纳米颗粒(免疫纳米颗粒,INPs),并装载了亲脂性紫杉醇棕榈酸酯(pcpl)前药。合成了Oleyl半胱氨酸酰胺(OCA),其两亲性质使PLGA NP的界面锚定和巯基表面功能化,从而促进了通过硫醚键与西妥昔单抗的生物缀合。事实证明,在过度表达EGFR的肺癌细胞中,这种靶向递送系统的体外靶向效率以及改善的细胞内在化和细胞毒性。使用表面等离子体共振证明了INPs对EGFR的高结合亲和力的定量测量。据报道在转移性肺癌模型中西妥昔单抗ppl1 INP的体内耐受性和增强的功效。使用非侵入性生物发光成像显示了其对A549-luc-C8肺肿瘤的治疗效果。与非靶向药物溶液,载有药物的纳米颗粒或空白INP相比,西妥昔单抗pcpl INP静脉注射给小鼠可导致对